Objective: To analyze the association between serum levels of S100A8/S100A9 and clinicopathological features of colorectal cancer patients.
Methods: A total of 82 patients with CRC and 14 healthy controls were enrolled for this study. The levels of S100A8 and S100A9 in serum were detected by ELISA assay. The association between S100A8/S100A9 and clinicopathological features was analyzed by student-t test and one-way ANOVA. Receiver Operating Characteristic curve was used to analyze diagnostic efficiency of serum S100A8 and S100A9 for colon rectal cancer. Logistic regression model was also established to analyze the possible risk factors for elevation of S100A8/S100A9.
Results: The levels of S100A8 and S100A9 were (1 403.3±593.7) and (2 890.3±994.9) pg/mL in patients with colon cancer, and (712.8±265.3) and (1 492.7±564.6) pg/mL in controls, respectively, with significant difference between the two groups (P<0.01). The similar results were found in rectal cancer patients, with a level of S100A8 and S100A9 at (1 417.7±666.5) and (3 026.7±887.6) pg/mL, respectively. Diagnostic sensitivity and specificity of S100A8 and S100A9 are better than traditional biomarkers. The levels of S100A9 in serum of CRC patients were correlated with clinical stages and distant metastasis. Serum levels of S100A9 in patients of stage III [(3 111.9±178.5) pg/mL] and stage IV [(3 831.4±278.5) pg/mL] were significantly (P<0.01) higher than that in stage I [(2 276.1±167.4) pg/mL], whereas there was significant change in S100A8 levels. Logistic regression showed the possible risk factors for the elevation of S100A9, including depth of invasion, lymphatic metastasis and degree of differentiation (P<0.05).
Conclusion: Serum level of S100A8 and S100A9 in CRC patients were significantly increased and serum level of S100A9 was positively correlated with the malignant features of CRC.
目的：探讨血清S100A8和S100A9表达水平和结直肠癌患者临床特征的关系。方法：用ELISA法检测82例结肠癌或直肠癌患者和14例健康对照者血清中S100A8和S100A9的含量，利用t检验、方差分析等方法分析两种分子与结直肠癌病理分期及临床特征的关系；利用受试者工作特征曲线(ROC曲线)分析S100A8和S100A9对结肠癌和直肠癌的诊断效能；构建logistic回归模型分析S100A8和S100A9血清水平升高的可能相关因素。结果：结肠癌组患者血清中S100A8浓度[(1 403.3±593.7) pg/mL]和S100A9的含量[(2 890.3±994.9) pg/mL]均显著高于健康对照组[分别为(712.8±265.3)和(1 492.7±564.6) pg/mL，P<0.01]；直肠癌患者血清S100A8和S100A9的含量分别是(1 417.7±666.5)和 (3 026.7±887.6) pg/mL，也高于对照组(P<0.05)；血清S100A8和S100A9诊断结肠癌或直肠癌均具有较高的敏感性和特异性，两者联合应用时，曲线下面积(AUC)在结肠癌和直肠癌分别达到0.972和0.964；随着结直肠癌临床恶性度增高和远处转移的发生，血清S100A9表达水平升高，差异具有统计学意义(P<0.05)，S100A9在III期[(3 111.9±178.5) pg/mL]和IV期[(3 831.4±278.5) pg/mL]患者血清中的含量均显著高于I期患者[(2 276.1±167.4) pg/mL，P<0.01]；而S100A8血清浓度与临床分期之间未发现明显关联；logistic回归分析发现血清S100A9升高与肿瘤浸润深度(OR=6.135，P=0.024)、淋巴结转移(OR=4.735，P=0.05)及分化程度(OR=2.573，P=0.043)等密切相关。结论：结直肠癌患者的S100A8和S100A9血清水平显著升高，且S100A9水平与结直肠癌恶性度呈正相关。.